Is There a Role for Immunotherapy in Prostate Cancer?
In the last decade, immunotherapy has revolutionized the treatment landscape of several hematological and solid malignancies, reporting unprecedented response rates. Unfortunately, this is not the case for metastatic castration-resistant prostate cancer (mCRPC), as several phase I and II trials asse...
Main Authors: | Alessandro Rizzo, Veronica Mollica, Alessia Cimadamore, Matteo Santoni, Marina Scarpelli, Francesca Giunchi, Liang Cheng, Antonio Lopez-Beltran, Michelangelo Fiorentino, Rodolfo Montironi, Francesco Massari |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-09-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/9/9/2051 |
Similar Items
-
Immune checkpoint inhibitors and prostate cancer: a new frontier?
by: Alessandra Modena, et al.
Published: (2016-04-01) -
New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen
by: Alessia Cimadamore, et al.
Published: (2018-12-01) -
Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer
by: Rodolfo Montironi, et al.
Published: (2020-04-01) -
Microbiome and Cancers, With Focus on Genitourinary Tumors
by: Alessia Cimadamore, et al.
Published: (2019-03-01) -
Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer
by: Veronica Mollica, et al.
Published: (2019-01-01)